Negara: Selandia Baru
Bahasa: Inggris
Sumber: Medsafe (Medicines Safety Authority)
Mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg
Pharmaco (NZ) Ltd
Mefloquine hydrochloride 274.09 mg (= mefloquine base 250mg)
250 mg
Tablet
Active: Mefloquine hydrochloride 274.09mg equivalent to mefloquine base 250mg Excipient: Crospovidone ammonium calcium alginate Lactose monohydrate Magnesium stearate Maize starch Microcrystalline cellulose Poloxamer Purified talc
Blister pack, 8 tablets
Prescription
Prescription
Siegfried Evionnaz SA
Chemoprophylaxis, therapy and stand-by treatment of malaria. Chemoprophylaxis Chemoprophylaxis with Lariam is recommended for travellers to malarious areas, particularly those travelling to areas where there is a high risk of infection with strains of P. falciparum resistant to other antimalarials. Therapy Lariam is indicated for the oral treatment of malaria, particularly when caused by strains of P. falciparum resistant to other antimalarials. It may also be used for the treatment of P. vivax and mixed malaria. Stand-by treatment Lariam is also prescribed as a stand-by medication, to be carried by the traveller and self-administered as an emergency measure for suspected malaria when prompt medical attention is unavailable within 24 hours.
Package - Contents - Shelf Life: Blister pack, - 8 tablets - 36 months from date of manufacture stored at or below 30°C. Store in original packge. Sensitive to moisture.
1990-08-06
Lariam ® CMI 180918 1 New Zealand Consumer Medicine Information LARIAM ® _MEFLOQUINE HYDROCHLORIDE _ 250 mg tablets WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Lariam tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Lariam tablets against the benefits expected for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT LARIAM IS USED FOR Lariam contains the active ingredient mefloquine. Lariam is used for the treatment and prevention of malaria, particularly malaria caused by the _Plasmodium falciparum _parasite resistant to other anti-malarial medicines. It can also be used as a stand-by treatment to be carried by the traveller and taken for suspected malaria when prompt medical attention is not available within 24 hours or more. Lariam belongs to a group of medicines called quinolones (pronounced _kwin-o-lones_). Lariam works by killing the parasites that may cause or have caused malaria. _WHERE AND HOW YOU CAN CONTRACT MALARIA _ Malaria is an infectious disease that is widespread in tropical and subtropical areas of Africa, Latin America, Asia and countries around the Pacific. There are different forms of malaria, each of them caused by a specific parasite transmitted to humans by the bite of the Anopheles mosquito. Lariam ® CMI 180918 2 _PRECAUTIONS AGAINST MALARIA _ The best protection against malaria is to avoid mosquito bites. The mosquito that causes malaria mainly bites between dusk and dawn. Therefore, the following precautionary measures are recommended: • during this period, wear light-coloured clothing that covers as much of your skin as possible. • apply mosquito repellent to your uncovered skin and to your clothes. • when sleeping in rooms that are not protected against mosquitoes, use an effec Baca dokumen lengkapnya
NEW ZEALAND DATA SHEET _ _ LARIAM001 07 DEC 2018 1 LARIAM ® 250 MG TABLETS Mefloquine hydrochloride 1 PRODUCT NAME Lariam 250 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 274.09 mg racemic mefloquine hydrochloride, equivalent to 250 mg mefloquine base. Excipient(s) with known effect: Lactose For full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Lariam 250 mg tablets are white, cross-scored cylindrical and biplane, marked "RO", "C", "HE" and an imprinted hexagon on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Chemoprophylaxis, therapy and stand-by treatment of malaria. _ _ CHEMOPROPHYLAXIS Chemoprophylaxis with Lariam is recommended for travellers to malarious areas, particularly those travelling to areas where there is a high risk of infection with strains of _P. falciparum_ resistant to other antimalarials. THERAPY Lariam is indicated for the oral treatment of malaria, particularly when caused by strains of _ P. _ _falciparum _ resistant to other antimalarials. It may also be used for the treatment of _ P. vivax _ and mixed malaria (see Section 4.2). STAND-BY TREATMENT Lariam is also prescribed as a stand-by medication, to be carried by the traveller and self- administered as an emergency measure for suspected malaria when prompt medical attention is unavailable within 24 hours. 4.2 DOSAGE AND ADMINISTRATION Mefloquine has a bitter and slightly burning taste. Lariam tablets should be swallowed whole, with at least one glass of liquid. The tablets may be crushed and suspended in a small amount of water, milk or other beverage for administration to small children and other persons unable to swallow them whole. NEW ZEALAND DATA SHEET _ _ LARIAM001 07 DEC 2018 2 _CHEMOPROPHYLAXIS STANDARD DOSAGE _ The recommended chemoprophylactic dose of Lariam is approximately 5 mg/kg bodyweight once weekly: Bodyweight (kg) Dose 5 – 20 kg ¼ tablet > 20 – 30 kg ½ tablet > 30 – 45 kg ¾ tablet > 45 kg 1 tablet Weekly doses should be taken regularly, Baca dokumen lengkapnya